



IMMUNO-model
Modelling immunotherapy response
and toxicity in cancer



Models, challenges and promises of advanced therapies for cancer: NK cells in the clinic and industry

Madrid, March 5–6th, 2026

Preliminary program

Thursday, March 5th, 9:00 -18:15 (registration from 8:00)

Session 1: Tumour recognition by NK cells

Coffee

Session 2: NK cell enhancer biomolecules

Sponsor talks

Break for lunch

Session 3: Successful NK cell-based therapies in the clinics

Round table 1: Introduction by experts and discussion. Regulatory aspects: how to understand guidelines for experimental design, how to adapt research to adapt GMP conditions, how to reach regulatory agencies

Poster session 1

Friday, March 6th, 9:00 -18:00 (registration from 8:00)

Session 3: Successful NK cell-based therapies in the clinics (continued)

Coffee

Round table 2: Introduction by experts and discussion. The clean room and therapeutics production

Break for lunch

Round table 3: Introduction by experts and discussion. Advanced therapies from the lab to industry. Science, investment and business aspects

Poster session 2

Session 4: Spotlight on pioneering strategies for immunotherapy

Concluding remarks, prizes and farewell

Confirmed speakers and round table experts (alphabetical order)

- Dr. **Belén Álvarez Palomo** (Banc de Sang i Teixits, Vall d'Hebron Institute of Research, Barcelona)
- Prof. **Luis Álvarez-Vallina**, CNIO and Hospital 12 de octubre
- Prof. **Todd Fehniger** (Washington University, St. Louis)
- Prof. **Ulrike Kohl** (Director of the Institute of Clinical Immunology, Leipzig, and Zelluna Immunotherapy)
- Prof. **Dean Lee**, Nationwide Children's Hospital and The Ohio State University Comprehensive Cancer Center
- Dr. **Sheila López Cobo** (Citospin, S.L. and CSIC)
- Prof. **Jordan Orange** (Children's Hospital of Philadelphia)
- Dr. **Carolina Pola** (CEO Stab therapeutics)
- Dr. **Marisol Quintero** (CEO Highlight therapeutics)
- Prof. **David Raulet** (University of California, Berkeley & Co-founder Dragonfly Inc)
- Prof. **Katy Rezvani**, online talk, (Institute for Cell Therapy Discovery & Innovation, Stem Cell Transplant and GMP Laboratories, Houston, Texas)
- Dr. **Rizwan Romee** (Dana Farber Cancer Institute, Harvard Medical School)
- Dr. **Sol Ruiz**, Head of Biologics, Advanced Therapies, and Biotechnology, Spanish Medicines Agency (AEMPS)
- Dr. **Charo Sánchez Pernauta** (Biocruces Hospital, Bilbao)
- Prof. **Eric Vivier** (Aix-Marseille University)
- **Invivo partners**